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Background: It remains unclear whether P2Y12 monotherapy, especially clopidogrel, following short-
-duration dual antiplatelet therapy (DAPT) is associated with favorable outcomes in patients undergoing 
complex percutaneous coronary intervention (PCI). Therefore, this study analyzed the efficacy and safety 
of P2Y12 inhibitor monotherapy, mostly clopidogrel (78%), in complex PCI following short-term DAPT.
Methods: The post-hoc analysis of the SMART-CHOICE trial involving 2,993 patients included 498 
cases of complex PCIs, defined by at least one of the following features: 3 vessels treated, ≥ 3 stents im-
planted, ≥ 3 lesions treated, bifurcation with ≥ 2 stents implanted, and a total stent length of ≥ 60 mm. 
The primary endpoint was major adverse cardiac and cerebrovascular event (MACCE), defined as the 
composite of all-cause death, myocardial infarction, and stroke. The primary safety endpoint included 
bleeding, defined as Bleeding Academic Research Consortium (BARC) types 2 to 5. 
Results: Complex PCI group had a higher risk of MACCE (4.0% vs. 2.3%, hazard ratio [HR] = 1.74, 
95% confidence interval [CI]: 1.05–2.89, p = 0.033) and a similar risk of BARC types 2–5 bleeding 
(2.6% vs. 2.6%, HR = 1.02, 95% CI: 0.56–1.86, p = 0.939) compared with those without complex 
PCIs. Patients undergoing complex PCIs, followed by P2Y12 inhibitor monotherapy and 12 months of 
DAPT exhibited similar rates of MACCE (3.8% vs. 4.2%, HR = 0.92, 95% CI: 0.38–2.21, p = 0.853). 
Conclusions: P2Y12 inhibitor monotherapy, mostly clopidogrel, following 3 months of DAPT did not 
increase ischemic events in patients with complex PCIs. (Cardiol J 2021; 28, 6: xx-xx)
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Introduction
With the development of new-generation drug-
-eluting stents (DES), several studies including 
GLOBAL-LEADERS, TWILIGHT, TICO, and the 
SMART-CHOICE trial have reported the safety 
and effectiveness of P2Y12 monotherapy follow-
ing short-term dual antiplatelet therapy (DAPT) 
[1–4]. However, short-term DAPT therapy in 
complex percutaneous coronary intervention (PCI) 
remains a concern. The concept of complex PCI 
has been recently proposed [5]. However, there is 
currently no universal definition of a complex PCI. 
In general, complex PCI includes bifurcation with 
2 stent implants, ≥ 3 stents implanted, ≥ 3 lesions 
treated, and total stent length ≥ 60 mm or stent 
with chronic total occlusion lesions [6]. Patients 
with complex PCIs carry a higher risk of ischemic 
adverse events that is proportional to their burden 
and severity of coronary artery disease [7], and re-
quire longer DAPT to prevent ischemic events [8]. 
Although prolonged DAPT is associated with 
a potential benefit in preventing ischemic events, 
it also increases bleeding risk, which is correlated 
with the morbidity and mortality of patients [9]. 
Sub-group analyses of complex PCI focusing on 
monotherapy with ticagrelor, but not clopidogrel 
which is used more in real-world practice showing 
favorable ischemic outcomes [6, 10].
The aim of this present sub-study of the 
SMART-CHOICE trial was to investigate the effec-
tiveness and safety of P2Y12 inhibitor monotherapy, 
mostly clopidogrel (78%), following short-term 
DAPT in patients with complex PCI compared with 
12 months of DAPT.
Methods
Study design
This study involved a post-hoc analysis of the 
SMART-CHOICE trial, a multicenter, prospective 
open-label randomized clinical trial (NCT02079194). 
The study design and protocol have been reported 
in detail elsewhere [2]. In brief, the trial random-
ly assigned patients to two groups before PCI: 
(i) 3 months of DAPT (acetylsalicylic acid [ASA] 
and a P2Y12 inhibitor), followed by 9 months of P2Y12 
inhibitor monotherapy, and (ii) 12 months of DAPT. 
The trial was designed and coordinated by the Aca-
demic Clinical Research Organization of Samsung 
Medical Center (Seoul, Korea). The trial randomized 
a total of 2,993 patients at 33 hospitals. This trial was 
approved by the Institutional Review Board of each 
center. The study followed the ethical principles of 
the Declaration of Helsinki. All patients provided 
written informed consent before participating in 
the trial. Patients and the public were not involved 
in the design of conduct in this research.
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Study proceedings
In the present analysis, complex PCI was de-
fined by at least one of the following angiographic 
characteristics: 3 vessels treated, ≥ 3 stents im-
planted, ≥ 3 lesions treated, bifurcation PCI with 
≥ 2 stents, and a total stent length of ≥ 60 mm. 
These five high-risk features of complex percuta-
neous procedures for ischemic events have been 
reported in previous studies [10].
Study endpoints
The primary efficacy endpoint included ma-
jor adverse cardiac and cerebrovascular event 
(MACCE) defined as a composite of all-cause 
death, myocardial infarction (MI), and stroke at 
1 year after the index procedure. The primary safe-
ty endpoint was bleeding defined as Bleeding Aca-
demic Research Consortium (BARC) types 2 to 5 at 
12 months after the index procedure. 
Definitions
Unless a definite noncardiac cause could be es-
tablished, cardiac disease was assumed as the default 
cause of death. Myocardial infarction was defined as 
elevated cardiac enzyme levels (cardiac troponin or 
myocardial band fraction of creatine kinase) above the 
upper reference limits with ischemic symptoms or 
electrocardiographic findings indicative of ischemia. 
However, periprocedural enzyme elevations within 
48 hours after the index procedure without concomi-
tant ischemic symptoms or electrocardiographic 
findings indicative of ischemia were excluded from 
the endpoint assessment. Stroke was defined as any 
nonconvulsive focal or global neurologic deficit of 
abrupt onset lasting more than 24 hours or leading 
to death caused by cerebral ischemia or hemor-
rhage. Stent thrombosis was defined as definite or 
probable type according to the Academic Research 
Consortium classification [11]. Major bleeding was 
defined as BARC types 3, 4, and 5 [12].
Statistical analysis
Categoric variables are presented as numbers 
and percentages and were compared using the 
c2 test or the Fisher exact test. Continuous varia-
bles are presented as the mean ± standard devia-
tion and compared using the Student t-test. The 
cumulative incidence of clinical events up to 1 year 
was calculated using the Kaplan-Meier method 
and compared using the log-rank test. The hazard 
ratio (HR), with a 95% confidence interval (CI) 
was derived from a Cox regression model. Sub-
group analyses of the outcomes were performed to 
evaluate the effects of P2Y12 inhibitor monotherapy 
compared with DAPT using Cox regression models 
with tests for interaction. All tests were two-sided 
and a p-value of < 0.05 was considered statistically 
significant. All analyses were performed using 
R version 3.5.0 (R Foundation for Statistical Com-
puting, Vienna, Austria).
Results
The SMART-CHOICE trial randomized 
a total of 2,993 patients including 498 treated with 
complex PCIs and 2,495 undergoing non-complex 
PCIs. The prevalence of complex PCI components 
in the overall population is shown in Figure 1. The 
baseline clinical and procedural characteristics ac-
cording to PCI complexity are summarized in Table 1. 
Of the patients, 76.3% (380/498) who underwent 
complex PCIs and 83.8% (1961/2495) of those 
who underwent non-complex PCIs were exposed 
to clopidogrel-based therapy. Patients undergoing 
complex PCIs manifested higher rates of hyperten-
sion, diabetes mellitus, and chronic renal failure, 
but lower rate of prior revascularization, and low 
ejection fraction. Angiographically, the complex 
PCI group had more diseased, treated lesions, 
and total stents implanted, with increased usage 
of intravascular ultrasound.
At 1 year, the patients who underwent complex 
PCIs carried higher rates of MACCE (4.0% vs. 2.3%, 
HR = 1.74, 95% CI: 1.05–2.89, p = 0.033), all-cause 
death (2.6% vs. 1.0%, HR = 2.52, 95% CI: 1.30–4.90, 
p = 0.007), cardiac death (1.6% vs. 0.6%, HR = 2.51, 
95% CI: 1.08–5.88, p = 0.033), and stent thrombo-
sis (0.6% vs. 0.1%, HR = 7.53, 95% CI: 1.26–45.06, 
p = 0.027). However, BARC bleeding types 2–5 
showed similar rates (2.6% vs. 2.6%, HR = 1.02, 
95% CI: 0.56–1.86, p = 0.939) in the complex and 
non-complex PCI groups (Table 2, Fig. 2).
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Table 1. Baseline and procedural characteristics in patients according to percutaneous coronary  
intervention (PCI) complexity
Complex PCI (n = 498) Non-complex PCI (n = 2495) P value
Age [years] 64.4 ± 10.7 64.5 ± 10.7 0.755
Male 376 (75.5%) 1822 (73.0%) 0.220
Body mass index 24.7 ± 3.1 24.6 ± 3.1 0.340
Hypertension 340 (68.3%) 1500 (60.1%) 0.001
Diabetes mellitus 218 (43.8%) 904 (36.3%) 0.002
Dyslipidemia 222 (44.6%) 1130 (45.5%) 0.767
Current smoking 127 (25.5%) 664 (26.7%) 0.630
Prior myocardial infarction 18 (3.6%) 109 (4.4%) 0.520
Prior revascularization 44 (8.8%) 305 (12.2%) 0.037
Prior stroke 41 (8.2%) 160 (6.4%) 0.168
Chronic renal failure 28 (5.6%) 69 (2.8%) 0.002
LVEF [%] 58.1 ± 11.9 60.3 ± 10.5 < 0.001
Acute coronary syndrome 288 (57.8%) 1453 (58.3%) 0.891
Shorter DAPT 260 (52.2%) 1235 (49.5%) 0.350
Clopidogrel based therapy 380 (76.3%) 1961 (83.8%) 0.258
Procedural characteristics
No. of diseased lesion/patient 2.39 ± 0.85 1.23 ± 0.47 < 0.001
No. of lesions stented/patient 2.37 ± 0.78 1.18 ± 0.38 < 0.001
No. of stents implanted/patient 2.75 ± 0.78 1.22 ± 0.43 < 0.001
Target vessels:
Left main 9 (1.8%) 49 (2.0%) 0.957
Left anterior descending 382 (76.7%) 1471 (59.0%) < 0.001
Left circumflex 235 (47.2%) 540 (21.6%) < 0.001
Right coronary 313 (62.9%) 735 (29.5%) < 0.001
Trans radial approach 367 (73.7%) 1815 (72.7%) 0.704
Use of IVUS 156 (31.5%) 622 (25.0%) 0.004
DAPT — dual antiplatelet therapy; IVUS —  intravascular ultrasound; LVEF — left ventricular ejection fraction
Table 2. Clinical outcomes in patients according to percutaneous coronary intervention (PCI) complexity.
Complex PCI  
(n = 498)





MACCE 20 (4.0%) 58 (2.3%) 1.74 (1.05–2.89) 0.033
Bleeding BARC type 2–5 13 (2.6%) 64 (2.6%) 1.02 (0.56–1.86) 0.939
All death: 13 (2.6%) 26 (1.0%) 2.52 (1.30–4.90) 0.007
   Cardiac death 8 (1.6%) 16 (0.6%) 2.51 (1.08–5.88) 0.033
   Non-cardiac death 5 (1.0%) 10 (0.4%) 2.52 (0.86–7.38) 0.091
Myocardial infarction 6 (1.2%) 22 (0.9%) 1.38 (0.56–3.40) 0.487
Stroke 3 (0.6%) 13 (0.5%) 1.16 (0.33–4.07) 0.816
Stent thrombosis 3 (0.6%) 2 (0.1%) 7.53 (1.26–45.06) 0.027
Major bleeding* 2 (0.4%) 24 (1.0%) 0.42 (0.10–1.77) 0.236
*BARC type 3 to 5 bleeding; BARC — Bleeding Academic Research Consortium; MACCE — major adverse cardiac and cerebrovascular event
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Baseline characteristics according to the an-
tiplatelet regimen used in patients with complex 
and non-complex PCIs are presented in Table 3. 
No significant differences were found in any vari-
ables. The effects of DAPT and P2Y12 inhibitor 
monotherapy in the complex and non-complex 
PCI groups are presented in Table 4 and Figure 3. 
In non-complex PCI, P2Y12 monotherapy showed 
similar MACCE rates (2.6% vs. 2.1%; HR = 1.27; 
95% CI: 0.76–2.14; p = 0.359) and significantly 
lower BARC 2–5 bleeding rates (1.9% vs. 3.3%; 
HR = 0.57; 95% CI: 0.34–0.96; p = 0.033) com-
pared with the DAPT group. Similar MACCE 
rates were found among patients exposed to P2Y12 
inhibitor monotherapy and DAPT (3.8% vs. 4.2%; 
HR = 0.92; 95% CI: 0.38–2.21; p = 0.853). P2Y12 
monotherapy was associated with lower BARC 
2–5 bleeding rates compared with the DAPT group 
without statistical significance (1.9% vs. 3.4%; 
HR = 0.58; 95% CI: 0.19–1.77; p = 0.340). The 
interaction was not statistically significant be-
tween complex and non-complex PCI groups with 
MACCE (interaction p = 0.483) and BARC bleed-
ing types 2–5 (interaction p = 0.904).  
Discussion
The current study compared the clinical out-
comes of patients treated with P2Y12 inhibitor mo-
notherapy, mostly clopidogrel, following 3 months 
of DAPT and 12 months of standard DAPT 
according to the PCI complexity. The findings of 
this study were as follows. First, patients undergo-
ing complex PCIs carried a higher risk of ischemic 
and similar risk of bleeding events than those with 
non-complex PCIs. Second, patients with complex 
PCIs treated with P2Y12 inhibitor monotherapy, 
mostly clopidogrel, following short-term DAPT 
showed favorable ischemic outcomes comparable 
to those 12 months of DAPT.
Regarding new-generation DESs, compared 
with standard DAPT, patients treated with PCI 
undergoing P2Y12 inhibitor monotherapy following 
short-term DAPT showed non-inferior ischemic 
outcomes [2]. P2Y12 inhibitor monotherapy reduced 
the risk of bleeding compared with DAPT [13]. 
These results suggest that P2Y12 inhibitor mono-
therapy after short-term DAPT might be compa-
rable to long-term DAPT for preventing ischemic 
events, with a lower risk of bleeding in patients 
undergoing PCIs with new-generation DESs. 
However, the risk-benefit profile of antiplatelet 
therapy regimens and their duration in patients 
with complex PCI remains disputed.
The concept of complex PCI has recently 
been proposed along with improvement in PCI 
techniques, adjunct pharmacological therapy, and 
the development of new-generation DES. How-
ever, currently, there is no universal definition of 
complex PCI in terms of angiographic or lesion 
characteristics. In the present study, the definition 
proposed by Serruys et al. [10], was used.
Figure 2. Cumulative incidence of events at 1 year on crude analysis according to complex and non-complex per-
cutaneous coronary interventions (PCI); A. Major adverse cardiovascular and cerebrovascular events (MACCE); 
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The study pooled patient-level data from 
6 randomized controlled trials and compared long-
term (≥ 12 months) and short-term (3 or 6 months) 
DAPT following ASA monotherapy in patients 
undergoing complex PCIs. The results showed that 
long-term DAPT significantly reduced MACCEs 
compared with short-term DAPT in the complex 
PCI group. That study also found that the benefit 
of long-term DAPT was increased additively with 
each increase in procedural complexity. However, 
the ischemic benefit of extended DAPT was offset 
by an increased risk of bleeding [14].
P2Y12 inhibitor monotherapy has been sug-
gested as a new alternative antiplatelet strategy to 
ASA because it reduced the cardiovascular events 
and gastrointestinal bleeding [15]. Recently, 4 large 
randomized clinical trials showed favorable results 
with P2Y12 inhibitor monotherapy after short-term 
DAPT. Among them, sub-analyses of the Global 
Leaders and TWILIGHT trials showed efficacy 
and safety of ticagrelor monotherapy in complex 
PCI. A post-hoc study of the Global Leaders trial 
revealed that 23 months of ticagrelor monotherapy 
following 1 month of DAPT provided a net clinical 
benefit for patients with complex PCIs [10]. The 
post-hoc study of the TWILIGHT trial showed 
that ticagrelor monotherapy was associated with 
a lower incidence of bleeding without an increased 
risk of ischemic events compared with continuing 
ticagrelor plus ASA for 12 months among patients 
undergoing complex PCIs [6]. In contrast to the 
previous 2 sub-studies, the present study used 
Table 3. Baseline and procedural characteristics stratified according to percutaneous coronary  
intervention (PCI) complexity and randomized regimen.












Age [years] 64.7 ± 10.5 64.0 ± 10.9 0.458 64.6 ± 10.8 64.4 ± 10.6 0.695
Male 191 (73.5%) 185 (77.7%) 0.316 896 (72.6%) 926 (73.5%) 0.628
Body mass index 24.6 ± 3.3 24.8 ± 2.9 0.680 24.5 ± 3.1 24.7 ± 3.2 0.101
Hypertension 177 (68.1%) 163 (68.5%) 0.978 744 (60.3%) 756 (60.0%) 0.914
Diabetes mellitus 119 (45.8%) 99 (41.6%) 0.397 451 (36.6%) 453 (36.0%) 0.766
Dyslipidemia 115 (44.2%) 107 (45.0%) 0.942 558 (45.3%) 572 (45.7%) 0.904
Current smoking 67 (25.8%) 60 (25.2%) 0.968 357 (29.0%) 307 (24.4%) 0.072
Prior myocardial infarction 9 (3.5%) 9 (3.8%) 0.987 53 (4.3%) 56 (4.4%) 0.929
Prior revascularization 19 (7.3%) 25 (10.5%) 0.272 153 (12.4%) 152 (12.1%) 0.840
Prior stroke 22 (8.5%) 19 (8.0%) 0.975 77 (6.2%) 83 (6.6%) 0.789
Chronic renal failure 16 (6.2%) 12 (5.0%) 0.731 28 (2.3%) 41 (3.3%) 0.168
LVEF [%] 58.3 ± 10.9 57.9 ± 11.6 0.657 60.2 ± 10.1 60.2 ± 9.8 0.950
Acute coronary syndrome 142 (54.6%) 146 (61.3%) 0.153 728 (58.9%) 725 (57.6%) 0.163
Clopidogrel based therapy 198 (76.2%) 182 (76.5%) 0.934 967 (78.3%) 994 (78.9%) 0.720
Procedural characteristics
No. of diseased lesion/patient 2.39 ± 0.95 2.39 ± 0.79 0.336 1.23 ± 0.40 1.23 ± 0.51 0.307
No. of lesions stented/patient 2.37 ± 0.58 2.37 ± 0.91 0.144 1.18 ± 0.41 1.18 ± 0.36 0.381
No. of stents implanted/patient 2.75 ± 0.82 2.75 ± 0.71 0.347 1.22 ± 0.41 1.22 ± 0.45 0.662
Target vessels:
Left main 5 (1.9%) 4 (1.7%) 0.419 20 (1.6%) 29 (2.3%) 0.279
Left anterior descending 193 (74.2%) 189 (79.4%) 0.208 710 (57.5%) 761 (60.4%) 0.151
Left circumflex 123 (47.3%) 112 (47.1%) 0.853 276 (22.3%) 264 (21.0%) 0.425
Right coronary 156 (60.0%) 157 (66.0%) 0.199 368 (29.8%) 367 (29.1%) 0.746
Trans radial approach 191 (73.5%) 176 (73.9%) 0.983 900 (72.9%) 915 (72.6%) 0.922
Use of IVUS 82 (31.7%) 74 (31.2%) 0.954 290 (23.6%) 332 (26.4%) 0.110
DAPT — dual antiplatelet therapy; IVUS —  intravascular ultrasound; LVEF — left ventricular ejection fraction
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Table 4. Comparison of clinical outcomes in patients stratified according to percutaneous coronary  
intervention (PCI) complexity and randomized regimen.
Percent (number) Hazard ratio P value Interaction p
P2Y12 monotherapy DAPT
MACCE:
Complex 3.8% (10/260) 4.2% (10/238) 0.92 (0.38–2.21) 0.853 0.483
Non-complex 2.6% (32/1235) 2.1% (26/1260) 1.27 (0.76–2.14) 0.359
Bleeding BARC type 2–5: 
Complex 1.9% (5/260) 3.4% (8/238) 0.58 (0.19–1.77) 0.340 0.904
Non-complex 1.9% (23/1235) 3.3% (41/1260) 0.57 (0.34–0.96) 0.033
All death:
Complex 3.1% (8/260) 2.1% (5/238) 1.48 (0.48–4.51) 0.494 0.646
Non-complex 1.1% (13/1235) 1.0% (13/1260) 1.03 (0.48–2.22) 0.942
Cardiac death:
Complex 1.9% (5/260) 1.3% (3/238) 1.54 (0.37–6.42) 0.557 0.671
Non-complex 0.5% (6/1235) 0.8% (10/1260) 0.62 (0.23–1.70) 0.351
Non-cardiac death:
Complex 1.2% (3/260) 0.8% (2/238) 1.39 (0.23–8.31) 0.719 0.210
Non-complex 0.6% (7/1235) 0.2% (3/1260) 2.40 (0.62–9.27) 0.205
Myocardial infarction: 
Complex 0.8% (2/260) 1.7% (4/238) 0.46 (0.09–2.53) 0.375 0.306
Non-complex 0.7% (9/1235) 1.0% (13/1260) 0.71 (0.31–1.67) 0.438
Stroke:
Complex 0% (0/260) 1.3% (3/238) 0.01 (0.01–153.1) 0.369 0.126
Non-complex 0.9% (11/1235) 0.2% (2/1260) 5.69 (1.26–25.67) 0.024
Stent thrombosis: 
Complex 0.8% (2/260) 0.4% (1/238) 1.82 (0.17–20.11) 0.624 0.320
Non-complex 0.1% (1/1235) 0.1% (1/1260) 1.02 (0.06–16.36) 0.987
Major bleeding: 
Complex 0% (0/260) 0.8% (2/238) 0.01 (0.01–125.1) 0.464 0.721
Non-complex 1.0% (12/1235) 1.0% (12/1260) 1.03 (0.46–2.30) 0.939
BARC — Bleeding Academic Research Consortium; DAPT — dual antiplatelet therapy; MACCE — major adverse cardiac and cerebrovascular 
event
P2Y12 inhibitor monotherapy, mostly clopidogrel, 
in more than three-quarters of the total study 
population following 3 months of DAPT. Although 
clopidogrel is most often used after PCI in real-
-world clinical practice, clopidogrel monotherapy 
may be inadequate in preventing ischemic events 
associated with complex PCIs due to less potency 
and wide individual variability of the drug response. 
Although the current study involved only East 
Asians who carry a lower ischemic risk than West-
erners, P2Y12 inhibitor monotherapy, mostly clopi-
dogrel, did not increase the ischemic risk compared 
with 12 months of DAPT. However, patients with 
P2Y12 monotherapy carrying non-complex lesions 
showed significantly lower bleeding rates (1.9% vs. 
3.3%; HR = 0.57, 95% CI: 0.34–0.96; p = 0.033) 
than patients with 12 months of DAPT, although 
the patients with complex PCIs did not show 
significantly lower bleeding rates (1.9% vs. 3.3%; 
HR = 0.58, 95% CI: 0.19–0.77; p = 0.340). The 
p-value for the interaction between the two treat-
ment arms was close to one, which is thought to be 
a type II statistical error due to the small sample 
size, and P2Y12 monotherapy also might have a fa-
vorable effect on bleeding events in complex PCIs. 
An expert consensus suggested that the selec-
tion and duration of the antiplatelet agents should 
be individualized by balancing ischemic and bleed-
ing risks. Accordingly, three scoring systems were 
developed, including the PRECISE-DAPT score to 
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facilitate the selection and duration of antiplate-
let agents for patients with high bleeding risk 
(PRECISE-DAPT score ≥ 25) [16]. In a study of 
patients who underwent complex PCI and using 
PRECISE-DAPT score, the long-term DAPT was 
associated with net adverse clinical events (NACE) 
only if the bleeding risk was low (PRECISE-DAPT 
score < 25) and no ischemic benefit and significantly 
higher bleeding events in patients with high bleed-
ing risk (PRECISE-DAPT score ≥ 25) [17]. In the 
present study of complex PCI stratified according to 
PRECISE-DAPT score, the high bleeding risk 
group was associated with higher rates of MACCE 
and NACE. In particular, the high bleeding risk 
group, unlike the low bleeding risk group, mani-
fested fewer BARC type 2–5 bleeding events and 
a HR 0.35 in the P2Y12 monotherapy group, without 
statistical significance due to the possibility of type 2 
error associated with small sample size (Suppl. 
Table 1). Another significant feature in this study 
was that intravascular ultrasound was used more 
in the complex PCI group, which may have affected 
lower ischemic events in the P2Y12 monotherapy 
group. Recently, the European Bifurcation Club 
proposed an algorithm for DAPT duration after PCI 
for bifurcation with a higher risk of both procedural 
and long-term adverse events. They proposed that 
decisions of DAPT duration should be based on the 
clinical presentation, bleeding risk, stenting strat-
egy, and the possible use of intracoronary imaging. 
When confirming coronary imaging during PCI, the 
duration of DAPT should be reduced [18].
Limitations of the study
The present study has notable strengths asso-
ciated with a well-randomized study design involv-
ing mainly clopidogrel but also had several limita-
tions. First, the present study on complex PCI 
was not pre-specified in the protocol. Therefore, 
the current findings must only be interpreted as 
hypothesis-generating. Confirmatory randomized 
trials for complex PCI with proper antiplatelet 
therapy are still needed in the future. Second, the 
complexity of coronary anatomy and lesions were 
site-reported, not reviewed by an angiographic core 
laboratory. Thus, they might not have included all 
angiographic markers of lesion complexity or risk. 
Third, in bleeding events of complex PCI, P2Y12 
inhibitor monotherapy resulted in fewer bleeding 
events without statistical significance due to type II 
error associated with a small sample size. Unfor-
tunately, the advantage of P2Y12 monotherapy with 
fewer bleeding events in complex PCIs could not 
be established. Fourth, the study findings cannot 
be generalized to Western patients because all 
patients were East Asians who were relatively 
resistant to ischemic events but more susceptible 
to bleeding events. 
Figure 3. Cumulative incidence of events at 1 year after randomization according to randomization group (dual 
antiplatelet therapy [DAPT] vs. P2Y12 monotherapy) in subjects with and without complex percutaneous coronary 
interventions (PCI); A. Major adverse cardiovascular and cerebrovascular events (MACCE); B. Bleeding Academic 
























P2Y  monotherapy vs. DAPT in complex PCI: HR 0.92 (95% CI 0.38–2.21)12
P2Y  monotherapy vs. DAPT in non-complex PCI: HR 1.27 (95% CI 0.76–2.14)12
Interaction P = 0.483
P2Y  monotherapy vs. DAPT in complex PCI: HR 0.58 (95% CI 0.19–1.77)12
P2Y  monotherapy vs. DAPT in non-complex PCI: HR 0.57 (95% CI 0.34–0.96)12








0 0120 120240 240
Days after initial procedure Days after initial procedure
Number at risk
Complex PCI/P2Y  monotherapy12
            260
Complex PCI/DAPT
            238
Non-complex PCI/P2Y  monotherapy12
          1235
Non-complex PCI/DAPT
          1260
Number at risk
Complex PCI/P2Y  monotherapy12
           260
Complex PCI/DAPT
           238
Non-complex PCI/P2Y  monotherapy12
          1235
Non-complex PCI/DAPT































Cardiology Journal 2021, Vol. 28, No. 6
Conclusions
In conclusion, compared with patients treated 
with non-complex PCIs, patients with complex 
PCIs carried a higher risk of ischemic events at 
1 year. P2Y12 inhibitor monotherapy, mostly with 
clopidogrel, following 3 months of DAPT resulted 
in favorable ischemic events comparable to the 
standard 12 months of DAPT regimen for com-
plex PCIs. These findings need to be considered 
as hypothesis-generating. This study should be 
viewed as a dedicated prospective trial of proper 
antiplatelet regimen for complex PCI.
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